Picktan Capital Eyes a Public Listing on the LSE
Picktan Capital Explores Strategic Move Toward Public Listing on the London Stock Exchange in 2026.
LONDON, UK / ACCESS Newswire / April 22, 2025 / Picktan Capital, the London-headquartered wealth management firm managing over $7 billion in client assets globally, has confirmed it is in active discussions with several major London-based investment banks to explore the possibility of a public listing on the London Stock Exchange (LSE) in 2026.
The firm, known for its disciplined investment approach and bespoke wealth solutions, has formally notified its board of directors and shareholders of its intent to pursue a potential IPO. A strategic review process is currently underway to evaluate the most effective path to the public markets. At a recent shareholder meeting, the proposal to move forward with the listing received unanimous approval, highlighting widespread confidence in the company's direction, leadership, and future growth prospects.
Founded with a mission to provide tailored, investment strategies to high-net-worth individuals, family offices, and institutions, Picktan Capital has seen consistent expansion over the past decade. The firm now services more than 9,000 clients across the UK, Europe, Asia, and the Middle East, supported by a team of seasoned investment professionals and a strong infrastructure rooted in risk management and long-term value creation.
A public offering would mark a transformational milestone for the company, providing access to additional growth capital and strengthening its presence in global markets. The move would also support ongoing efforts to expand its product offering, invest in next-generation technology platforms, and accelerate hiring across key operational and advisory areas.
"While no final decision has been made, we are rigorously evaluating all avenues for a listing," said Jacob Baker, CFO of Picktan Capital. "A move to go public would mark a transformative step for the business and allow us to broaden access to capital markets, scale more efficiently, and bring greater transparency and trust to our growing client base worldwide."
The company has reportedly drawn significant interest from top-tier investment banks based in London, with multiple firms actively positioning themselves to lead the offering. If confirmed, the IPO could be among the most notable financial services listings in 2026 - a sign of growing investor appetite for profitable, independently managed firms operating in the private wealth and asset management space.
In preparation for the potential listing, Picktan Capital has assembled a dedicated internal team to lead the IPO process, supported by external legal, regulatory, and financial advisors. The company is also reviewing potential governance changes and operational adjustments required to meet public market standards, including enhanced disclosure protocols and board restructuring.
Further announcements will be made in due course, as internal evaluations continue and market conditions develop. Shareholders will be kept informed throughout the process, with transparency and strategic alignment remaining at the core of all decisions.
About Picktan Capital
Founded in London, Picktan Capital is a global wealth management firm serving over 9,000 clients across Europe, North America, Asia, and the Middle East. The firm provides bespoke investment management, financial planning, and strategic advisory services to high-net-worth individuals, family offices, and institutions, with over $7 billion in assets under management.
Media Contact:
Sophie Hayworth
Media and PR Manager
Picktan Capital Limited
Email: media@picktancapital.com
Telephone Number: +44 (0)203 773 8881
Address: 1 Canada Square, London, E14 5AX, United Kingdom
SOURCE: Picktan Capital
View the original press release on ACCESS Newswire
Picktan Capital

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Sauce Labs Launches Industry-First Enterprise Scale iOS 18 Testing on Sauce Labs Virtual Device Cloud, Boosting Test Speeds up to 40%24.4.2025 08:00:00 CEST | Press release
Leading test automation platform, powering development for over 300,000 active users and having executed more than 8 billion tests, enables developers and QA teams to ensure app quality on Apple's latest OS with unprecedented performance and scale. SAN FRANCISCO, CA / ACCESS Newswire / April 24, 2025 / Sauce Labs Inc., the leading platform for continuous quality, trusted by dev teams around the world to deliver apps users love, today announced the general availability of iOS 18 testing on its Virtual Device Cloud (VDC). Leveraging its new, high-performance Apple Silicon cloud infrastructure, Sauce Labs offers the market's most scalable enterprise-ready solution for automated mobile app and web testing on iOS 17.5, iOS 18, and beyond, enabling teams to execute tests up to 40% faster compared to previous versions. This launch addresses the critical need for timely testing support driven by Apple's transition to its proprietary Apple Silicon architecture and the rapid adoption rate of new
Introducing NUGEN(R) HLD-CD by Arxada: A Game-Changer in Healthcare Disinfection24.4.2025 07:00:00 CEST | Press release
Delivering Effective Germ Control in Five Minutes BASEL, CH / ACCESS Newswire / April 24, 2025 / Arxada, a global leader in specialty chemicals and innovative solutions, announces the launch of NUGEN® HLD-CD, a revolutionary healthcare disinfectant. This game-changing solution disinfects medical devices in just five minutes, ensuring that even the most resilient microorganisms, which can withstand harsh conditions, are destroyed.* NUGEN® HLD-CD is designed to meet the rigorous demands of healthcare environments. Its broad efficacy spectrum and short contact times make it suitable for all critical areas, including operating rooms, isolation areas, and intensive care units where speed and safety are essential. "We are excited to introduce NUGEN® HLD-CD to the healthcare market," said Uwe Holland, Head of Professional Hygiene EMEA at Arxada. "This solution is a game-changer in disinfection technology for healthcare facilities, providing professionals with a powerful means to improve patie
TCL Introduces the TCL T6C-UK Fire TV Series with QLED 4K, HDR PRO, and Freely23.4.2025 07:30:00 CEST | Press release
LONDON, UNITED KINGDOM / ACCESS Newswire / April 23, 2025 / TCL, the leading consumer electronics brand and the world's second-largest TV brand as well as an official sponsor of the Olympic Games, is proud to announce the launch of its highly anticipated T6C-UK TV series. The new range offers screen sizes from 43" to 85", ensuring there is a perfect option for every home. Featuring QLED technology, 4K resolution, and an intuitive Fire TV experience, the T6C-UK series offers exceptional picture quality, seamless content access, and smart functionality. The TCL T6C-UK series comes Freely-enabled, offering a seamless way to enjoy live and on-demand TV - all in one place and completely free. With Freely built-in, users can access their favourite streaming apps at the click of a button, eliminating the need to switch between platforms. From major channels to must-watch shows, everything is easily accessible from a single, intuitive home screen. Powered by Fire TV, the T6C-UK series also fea
BioNxt Solutions Prepares for Human Bioequivalence Study For MS23.4.2025 03:05:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment. BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish. T
ToolsGroup Recognized in the 2025 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions for the Second Consecutive Year22.4.2025 09:00:00 CEST | Press release
As a trusted partner to retailers, distributors, and manufacturers, ToolsGroup drives results in an uncertain world BOSTON, MA / ACCESS Newswire / April 22, 2025 / ToolsGroup, a global leader in supply chain planning and optimization software, is proud to announce that it has been included in the 2025 Gartner Magic Quadrant for Supply Chain Planning Solutions for the second consecutive year. For retailers, distributors, and manufacturers struggling to deliver results amidst uncertainty, ToolsGroup provides a breakthrough approach to supply chain planning that combines statistical modelling, advanced mathematical optimization, and AI. Customers have the power to shape demand and synchronize supply - replacing guesswork with precision. Built on decades of expertise and a unique probabilistic approach, ToolsGroup's Supply Chain Planning capabilities cover everything from S&OP and demand planning to inventory optimization, replenishment, and transport analytics. Powered by AI and real-time
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom